Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2003-12-02
2008-12-02
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C424S093100
Reexamination Certificate
active
07459272
ABSTRACT:
The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.
REFERENCES:
patent: 4375734 (1983-03-01), Kozloff et al.
patent: 4891210 (1990-01-01), Norris
patent: 4957686 (1990-09-01), Norris
patent: 5132221 (1992-07-01), Ward et al.
patent: 5612182 (1997-03-01), Pearson et al.
patent: 5641464 (1997-06-01), Briggs, III et al.
patent: 5660812 (1997-08-01), Merril et al.
patent: 5688501 (1997-11-01), Merril et al.
patent: 5766892 (1998-06-01), Merril et al.
patent: 5811093 (1998-09-01), Merril et al.
patent: 6015816 (2000-01-01), Kostyniak et al.
patent: 6056954 (2000-05-01), Fischetti et al.
patent: 6121036 (2000-09-01), Ghanbari et al.
patent: 6322783 (2001-11-01), Takahashi
patent: 2005/0260171 (2005-11-01), Ghanbari et al.
patent: 37 14699 (1988-01-01), None
patent: 3714699 (1988-01-01), None
patent: 19 828696 (1999-02-01), None
patent: 198 28 596 (1999-02-01), None
patent: 0 290 295 (1988-11-01), None
patent: 0290295 (1988-11-01), None
patent: 0 414 304 (1991-02-01), None
patent: 0414304 (1991-02-01), None
patent: 0 510 907 (1992-10-01), None
patent: 0510907 (1992-10-01), None
patent: 2 253 859 (1992-09-01), None
patent: 2253859 (1992-09-01), None
patent: 62 123104 (1987-04-01), None
patent: 62-123104 (1987-06-01), None
patent: WO 90/13631 (1990-11-01), None
patent: WO 9013631 (1990-11-01), None
patent: 95 27043 (1995-10-01), None
patent: WO 95/27043 (1995-10-01), None
patent: 97 39111 (1997-10-01), None
patent: WO 97/39111 (1997-10-01), None
patent: 00 69269 (2000-11-01), None
patent: WO 00/69269 (2000-11-01), None
Barrow et al. Use of Lytic Bacteriophage for Control of ExperimentalEscherichia coliSepticemia and Meningitis in Chickens and Calves. Clinical and Diagnostic Laboratory Immunology. 5(3): 294-298. 1998.
Carlton, R. Phage Therapy: Past History and Future Prospects. Archivum Immunologiae et Therapiae Experimentalis 47: 267-274, 1999.
Risi et al. Prevention of infection in the immunocompromised host. Am J Infect Control 26: 594-604, 1998.
Kudva, Indira T., et al., “Biocontrol ofEscherichia coliO157 with O157-Specific Bacteriophages”, Applied and Environmental Microbiology, vol. 65, p. 3767-3773, 1999.
Lenski, Richard E., “Dynamics of Interactions Between Bacteria and Virulent Bacteriphage”, Adv. Microb., Ecol., vol. 10, p. 1-44, 1988.
Levin, Bruce R., et al., “Phage Therapy Revisited: The Population Biology of a Bacterial Infection and its Treatment with Bacteriophage and Antibiotics”, The American Naturalist, vol. 147, p. 881-898, 1996.
Ochs, Hans D., “Immunologic Responses to Bacteriophage φX 174 in Immunodeficiency Diseases”, The Journal of Clinical Investigation, vol. 50, p. 2559-2567, 1971.
Slopek, et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections; I. General Evaluation of the Results”, Arch. Immunol. Therapiae Exper., vol. 31, p. 267-291, 1983.
Slopek, et al., Results of Bacteriophage Treatment of Suppurative Bacterial Infections: II. Detailed Evaluation of the Results, Arch. Immunol. Therapiae Exper., vol. 31, p. 293-327, 1981.
Slopek, et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections; III. Detailed Evaluation of the Results Obtained in Further 150 cases”, Ach. Immunol. Therapiae Exper., vol. 32, p. 317-335, 1984.
Slopek, et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections; IV. Evaluation of the Results Obtained in 370 cases”, Arch. Immunol. Therapiae Exper., vol. 33, p. 219-240, 1985.
Slopek, et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections; V. Evauluation of the Results Obtained I Children”, Arch. Immunol. Therapiae Exper., vol. 33, p. 241-260, 1985.
Slopek, et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections; VI. Analysis of Treatment of Suppurative Staphylococcal Infections”, Arch. Immunol. Therapiae Exper., vol. 33, p. 261-275, 1985.
Slopek, et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections in the Years 1981-1986”, Arch. Immunol. Therapiae Exper., vol. 35, p. 569-584, 1987.
Soothill, J. S., “Bacteriophage Prevents Destruction of Skin Graft byPseudomonas aeruginosa”, Burns, vol. 20, p. 209-211, 1994.
Soothill, J.S., “Treatment of Experimental Infections of Mice with Bacteriophages”, J. Med. Microbiol., vol. 37, p. 258-261, 1992.
Alavidze, A., et al., “Isolation of Specific Lytic Phages Multidrug ResistantPseudomonas aeruginosa”, The American Society for Microbiology, vol. 99, p. 447, 1999. [Abstract Only].
Slopek, S., et al., “Results of Bacteriophage Treatment of Suppurative Bacterial Infections VI. Analysis of Treatment of Supparative Staphylococcal Infections”,Database Biosis ′Online, Biosciences Information Services, 1985. [Abstract Only].
Bogovazova, G. G., et al., “Immunobiological Properties & Therapeutic Effectiveness of Preparations from Klebsiella Bacteriophages”,Zh. Mikrobiol. Epidemiol. Immunobiol., vol. 3, p. 30-33, 1992. [Abstract Only].
Barrow, P. A., “Bacteriophages Mediating Somatic Antigenic Conversion inSalmonella cholerae-suis: their Isolation from Sewage and Other Salmonella Serotypes Processing the Somatic 6 Antigen”Journal of General Microbiology, vol. 132, p. 835-837, 1986.
Barrow, et al., “Salmonellosis—Prospects for Microbiological Control in Poultry”,Avian Pathology, vol. 18, p. 557-561, 1989.
Barrow, Paul A., et al., “Bacteriophage Therpay and Prophylaxis: Rediscovery and Renewed Assessment of Potential”,Trends in Microbiology, vol. 5, p. 268-271, 1997.
Berchieri, A., Jr., et al., The Activity in the Chicken Alimentary Tract of Bacteriophages Lytic forSalmonella typhimurium, Res. Microbiol., vol. 142, p. 541-549, 1991.
Williams Smith, H., et al., “Successful Treatment of ExperimentalEscherichia coliInfections in Mice Using Phage: Its General Superiority Over Antibiotics”,Journal of General Microbiology, vol. 128, p. 307-318, 1982.
Williams Smith, H., et al., “Effectiveness of Phages in Treating ExperimentalEscherichia coliDiarrhoea in Calves, Piglets and Lambs”,Journal of General Microbiology, vol. 129, p. 2659-2675, 1983.
Williams Smith, H., et al., The Control of ExperimentalEscherichia coliDiarrhoea in Calves by Means of Bacteriophages,Journal of General Microbiology, vol. 133, p. 1111-1126, 1987.
Soothill, J. S., et al., “The Efficacy of Phages in the Prevention of the Destruction of Pig Skin in vitro byPseudomonas aeruginosa”, Med. Sci. Res., vol. 16, p. 1287-1288, 1988.
Gachechiladze, K. K., et al., “Host-Controlled Modification and Restriction as a Criterion of Evaluating the Therapeutical Potential of Pseudomonas Phage”,J. Basic Microbiol., vol. 31, p. 101-106, 1991.
Adamia, Revaz S., et al., “The Virulent Bacteriophage IRA ofSalmonella typhimurium: Cloning of Phage Genes which are Potentially Lethal for the Host Cell”,J Basic Microbiol., vol. 30, p. 707-716, 1990.
Karin E. Byers et al., “Disinfection of Hospital Rooms Contaminated with Vancomyci-ResistantEnterococcu
Alavidze Zemphira
Brown Torrey C.
Morris J. Glenn
Pasternack Gary R.
Sulakvelidze Alexander
Guzo David
Hunton & Williams LLP
Intralytix, Inc.
Joike Michele K.
LandOfFree
Reduction in bacterial colonization by administering... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduction in bacterial colonization by administering..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction in bacterial colonization by administering... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4025343